These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14991758)

  • 21. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells.
    Gravina GL; Festuccia C; Angelucci A; Poletti A; Capuano D; Vicentini C; Motta M; Bologna M
    Int J Oncol; 2004 Jul; 25(1):97-104. PubMed ID: 15201994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
    Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
    Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
    Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
    Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme.
    Kanai M; Ishii K; Kanda H; Ogura Y; Kise H; Arima K; Sugimura Y
    Cancer Sci; 2008 Dec; 99(12):2435-43. PubMed ID: 19018772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
    Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
    J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
    Denmeade SR; Lin XS; Isaacs JT
    Prostate; 1996 Apr; 28(4):251-65. PubMed ID: 8602401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic implications of the revised concept of hormone-refractory metastatic prostate cancer].
    Paule B
    Prog Urol; 2004 Dec; 14(6):1119-24. PubMed ID: 15751404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical and biological study of androgen independent prostate cancer (AI PCa).
    Logothetis CJ; Hoosein NM; Hsieh JT
    Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155
    [No Abstract]   [Full Text] [Related]  

  • 39. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.